Pygeum: Bark Chemistry and Prostate Mechanisms

Table of Contents

1. What Is in the Bark
2. Beta-Sitosterol and the Phytosterols
3. Ferulic Acid Esters
4. Atraric Acid and the Androgen Receptor
5. Inflammation and the 5-Lipoxygenase Pathway
6. The DHT Theory of Prostate Growth
7. Prostate Cancer Cells and Mice: Laboratory Work Only
8. Bark Versus Products: the 2019 Comparison
9. Why One Extract Is Not Another
10. From Lab Result to Patient: the Gaps
11. A Glossary of the Laboratory Terms
12. Key Research Papers
13. Connections

What Is in the Bark

The bark is a complex mixture. A 1981 report in Planta Medica was among the first to describe its constituents. A 2019 analytical study from Oberlin College developed a liquid chromatography–mass spectrometry method to measure the compounds most often named as active, and listed them as:

• Atranorin — a small aromatic compound.
• Atraric acid — a small aromatic acid, discussed in detail below.
• Beta-sitosterol and its esters — plant sterols.
• Ferulic acid and its esters — a plant phenolic acid, mostly present in bound (ester) form.
• N-butylbenzene sulfonamide — reported in older work.

The authors described these as compounds "that have been shown to improve the conditions of benign prostatic hyperplasia". That phrase summarises earlier literature; it is not a finding of their study, which was purely chemical. Whether any one of these compounds, at the amount in a capsule, does anything in a human prostate has not been shown.

Back to Table of Contents

Beta-Sitosterol and the Phytosterols

Beta-sitosterol is one of the commonest plant sterols in the human diet, found in nuts, seeds, vegetable oils and avocados. It has its own BPH literature: a 2019 Italian review described beta-sitosterol as able to improve urinary symptoms and flow measures but not to reduce prostate size, and a 2023 US review listed beta-sitosterol alongside pygeum as herbal treatments that "may be effective".

The chemical comparison of bark and products produced the most striking result on this page:

• In the four bark samples, total beta-sitosterol was "relatively invariant at about 680 µg/g".
• Some of the seven commercial pygeum products had more than 10,000 µg/g — roughly fifteen times the bark level.
• About 33% of the bark's beta-sitosterol was in the free form; in the products, nearly all of it was free.
• Product sterol content generally followed the phytosterol amount stated on the label.

The study did not explain the difference. Either way, a man taking one of those products is getting a high-sterol preparation, and its effects may owe more to the sterols than to anything specific to Prunus africana. The study itself did not test any effects in people.

Back to Table of Contents

Ferulic Acid Esters

Ferulic acid is a common plant antioxidant (see the site's Ferulic Acid page). In pygeum bark, the 2019 study found that more than 90% of it was bound as esters in both bark and products. The difference was in quantity: total ferulic acid averaged about 450 µg/g in bark, roughly four times the average in the products.

So the products went in opposite directions on the two best-known compound groups — much more sterol, much less ferulic acid than the bark. For anyone trying to connect a mechanism to the clinical trials, this matters: the products tested in the older trials, the products on sale today, and the raw bark may differ in exactly the compounds proposed as active.

Back to Table of Contents

Atraric Acid and the Androgen Receptor

Male hormones (androgens) such as testosterone and dihydrotestosterone (DHT) act through the androgen receptor, a protein inside prostate cells that switches growth genes on. Blocking that receptor, or lowering androgen levels, is the basis of several prostate drugs.

A 2006 study from the University of Marburg used bioactivity-guided fractionation: the bark was extracted with dichloromethane, split into fractions, and each fraction tested for its ability to block the androgen receptor in a reporter-gene assay (cells engineered to produce a measurable signal when the receptor is switched on). The active compound they isolated was atraric acid. They then made ethyl, propyl and butyl versions of it and tested those as well, and also isolated benzoic acid.

This is solid laboratory chemistry. It identifies a bark compound with anti-androgen activity in engineered cells. It does not show how much atraric acid reaches the prostate after a capsule is swallowed, and the 2019 analysis found atraric acid at only low microgram-per-gram levels in both bark and products.

Back to Table of Contents

Inflammation and the 5-Lipoxygenase Pathway

BPH tissue often contains inflammatory cells, and one theory is that inflammation contributes to prostate growth and symptoms. A 1994 French laboratory study tested pygeum extract on human white blood cells (polymorphonuclear leukocytes, the neutrophil family) in a dish. The cells were stimulated with a calcium ionophore to make leukotrienes, inflammatory signalling molecules produced by the enzyme 5-lipoxygenase.

• Extract dissolved in DMSO significantly reduced the production of 5-lipoxygenase products (5-HETE, LTB4 and its metabolites) at concentrations as low as 3 micrograms per millilitre.
• A water-based form of the extract needed 10 micrograms per millilitre for an effect, which the authors attributed to poorer solubility of the active components.
• Cell viability stayed above 95% with both forms, so the effect was not simply the cells dying.

The authors proposed that this "may contribute, at least in part" to a therapeutic effect. That is a hypothesis. Whether blood or prostate concentrations in men ever reach a few micrograms per millilitre of the active fraction has not been measured in the pack studies.

A 2019 review summarised the properties sought from prostate herbs as anti-androgenic, anti-oestrogenic, antiproliferative, antioxidant and anti-inflammatory, and a 2000 review argued that pygeum and saw palmetto had both been subjects of basic-science work on mechanism.

Back to Table of Contents

The DHT Theory of Prostate Growth

A 2021 review of herbal BPH treatments summarised two of the leading theories of why the prostate grows with age:

• The oestrogen balance theory: testosterone falls with age, the testosterone-to-oestrogen ratio drops, and relatively greater oestrogen activity may promote prostate cell growth.
• The DHT theory: the enzyme 5-alpha-reductase converts testosterone to the more potent DHT; its activity rises with age, and DHT may promote prostate cell growth.

Some plant compounds are proposed to act on this enzyme or on these hormone pathways. A 2000 review written by scientists at a botanical-extract manufacturer described 5-alpha-reductase activity and prostate inflammation as the targets of standardised extracts of pygeum and saw palmetto. The pack contains no study that measured 5-alpha-reductase inhibition by pygeum in humans, and this page does not claim that it has one.

Back to Table of Contents

Prostate Cancer Cells and Mice: Laboratory Work Only

A 2007 University of Missouri study tested a 30% ethanol extract of pygeum in two settings:

• In cell culture, using two human prostate cancer cell lines (PC-3 and LNCaP): the extract inhibited growth, induced programmed cell death (apoptosis), altered the cell cycle, lowered levels of oestrogen receptor alpha and protein kinase C alpha, and bound to both oestrogen and androgen receptors.
• In TRAMP mice, a strain engineered to develop prostate cancer: mice fed pygeum had a prostate cancer incidence of 35%, against 62.5% in mice fed a casein control diet (p = 0.034).

The authors concluded that pygeum "may be a useful supplement for people at high risk". That conclusion goes beyond the data: it was a cell and mouse study, and no human trial of pygeum for preventing or treating prostate cancer exists in the published literature gathered for this page. A 2013 systematic review found no evidence to support phytotherapy in treating prostate adenocarcinoma, and only experimental-level work on prevention. Prostate cancer is covered on the site's Prostate Cancer page.

Back to Table of Contents

Bark Versus Products: the 2019 Comparison

Pulling the chemical-comparison results together:

• Similar in bark and products: atranorin and atraric acid (low µg/g), and the fact that ferulic acid is more than 90% esterified.
• Higher in bark: total ferulic acid, about four times higher on average (about 450 µg/g).
• Higher in some products: total beta-sitosterol, above 10,000 µg/g in some products versus about 680 µg/g in bark.
• Different form: free beta-sitosterol about 33% in bark versus nearly all in products.
• Absent everywhere: no N-butylbenzene sulfonamide in any bark or product sample.

The study was small — four bark samples and seven products — and it did not name the products in its abstract. It does show that "pygeum" on a label is not a fixed chemical description.

Back to Table of Contents

Why One Extract Is Not Another

Researchers on both sides of the pygeum debate agree on one point. A 2000 review of pygeum and saw palmetto mechanisms stated that each individual preparation, even from the same plant, "must be considered individually because of differences in the extraction techniques, preparation of products, composition, and biological activities". A 2002 review made the same argument from the clinical side, concluding that each manufacturer's preparation needs its own placebo-controlled trials.

The practical consequence is that laboratory findings for one extract (for example, the dichloromethane fraction that yielded atraric acid, or the 30% ethanol extract used in the mouse study) do not automatically apply to a different extract, and neither do the clinical trials.

Back to Table of Contents

From Lab Result to Patient: the Gaps

1. Absorption. No pack study measured blood or prostate levels of atraric acid, ferulic esters or the anti-inflammatory fraction after oral pygeum.
2. Dose matching. The concentrations active in cell studies have not been matched to the 100 mg daily doses used in the trials.
3. Which compound. No trial has tested an isolated bark compound against the whole extract.
4. Prostate size. In cells and mice, growth-related effects were seen; no pack study shows prostate shrinkage in men.
5. Cancer. All cancer data are cell and mouse data.

The mechanisms are plausible enough to keep researchers interested. They are not, on their own, a reason to expect any particular effect in a person.

Back to Table of Contents

A Glossary of the Laboratory Terms

• In vitro — "in glass": an experiment on cells or molecules in a dish or tube, not in a living animal or person.
• Cell line — a population of cells, often originally from a tumour, that can be grown indefinitely in the laboratory. PC-3 and LNCaP are two widely used human prostate cancer cell lines.
• Reporter-gene assay — cells engineered so that when a target such as the androgen receptor is switched on, they produce a measurable signal. A compound that lowers the signal is said to block the receptor.
• Bioactivity-guided fractionation — repeatedly splitting an extract into parts and testing each, keeping the active part, until a single active compound is isolated.
• Androgen receptor — the protein through which testosterone and DHT act on cells.
• 5-alpha-reductase — the enzyme that converts testosterone to dihydrotestosterone (DHT).
• 5-lipoxygenase — an enzyme that makes leukotrienes, inflammatory signalling molecules.
• Apoptosis — programmed cell death, a normal way the body removes unwanted cells.
• TRAMP mouse — a genetically engineered mouse that develops prostate cancer, used to test possible preventive agents.
• Ester — a chemical bond joining an acid (such as ferulic acid) to an alcohol; "free" and "esterified" forms of the same compound can behave differently in the body.
• µg/g — micrograms per gram, i.e. parts per million by weight.

Back to Table of Contents

Key Research Papers

1. Thompson RQ, Katz D, Sheehan B. Chemical comparison of Prunus africana bark and pygeum products marketed for prostate health. Journal of pharmaceutical and biomedical analysis. 2019;163:162-169. PubMed PMID: 30316061
2. Longo R, Tira S. Constituents of Pygeum africanum Bark. Planta medica. 1981;42(6):195-6. PubMed PMID: 17401960
3. Schleich S, Papaioannou M, Baniahmad A, et al. Activity-guided isolation of an antiandrogenic compound of Pygeum africanum. Planta medica. 2006;72(6):547-51. PubMed PMID: 16773539
4. Paubert-Braquet M, Cave A, Hocquemiller R, et al. Effect of Pygeum africanum extract on A23187-stimulated production of lipoxygenase metabolites from human polymorphonuclear cells. Journal of lipid mediators and cell signalling. 1994;9(3):285-90. PubMed PMID: 7921787
5. Shenouda NS, Sakla MS, Newton LG, et al. Phytosterol Pygeum africanum regulates prostate cancer in vitro and in vivo. Endocrine. 2007;31(1):72-81. PubMed PMID: 17709901
6. Csikós E, Horváth A, Ács K, et al. Treatment of Benign Prostatic Hyperplasia by Natural Drugs. Molecules (Basel, Switzerland). 2021;26(23). PubMed PMID: 34885733
7. Cicero AFG, Allkanjari O, Busetto GM, et al. Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica. 2019;91(3). PubMed PMID: 31577095
8. Levin RM, Das AK. A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens. Urological research. 2000;28(3):201-9. PubMed PMID: 10929430
9. Cristoni A, Di Pierro F, Bombardelli E. Botanical derivatives for the prostate. Fitoterapia. 2000;71 Suppl 1:S21-8. PubMed PMID: 10930709
10. Dreikorn K. The role of phytotherapy in treating lower urinary tract symptoms and benign prostatic hyperplasia. World journal of urology. 2002;19(6):426-35. PubMed PMID: 12022711
11. Morán E, Budía A, Broseta E, et al. [Phytotherapy in urology. Current scientific evidence of its application in benign prostatic hyperplasia and prostate adenocarcinoma]. Actas urologicas espanolas. 2013;37(2):114-9. PubMed PMID: 23058996
12. Arnold MJ, Gaillardetz A, Ohiokpehai J. Benign Prostatic Hyperplasia: Rapid Evidence Review. American family physician. 2023;107(6):613-622. PubMed PMID: 37327163
13. Wilt T, Ishani A, Mac Donald R, et al. Pygeum africanum for benign prostatic hyperplasia. The Cochrane database of systematic reviews. 2002;1998(1):CD001044. PubMed PMID: 11869585

PubMed Topic Searches

1. PubMed: Atraric acid and the androgen receptor
2. PubMed: Pygeum africanum mechanism of action
3. PubMed: Prunus africana bark phytosterols

Back to Table of Contents

Connections

• All Herbs
• Pygeum (Prunus africana) — the main topic page
• Pygeum Benefits Hub — all four deep dives
• BPH Evidence — the clinical side
• Overharvesting and CITES — the source of the bark
• Pygeum vs Saw Palmetto and Nettle — mechanisms compared
• Ferulic Acid — the phenolic acid in the bark
• Avocado — a food rich in beta-sitosterol
• Saw Palmetto: Hormonal Effects — 5-alpha-reductase and DHT
• Prostate Cancer — where pygeum has only lab data
• Benign Prostatic Hyperplasia — the condition
• Lycopene and Prostate Health — another plant compound studied for the prostate

Back to Table of Contents